Form 4: Dyadic COO Joseph Hazelton Boosts Stake with RSU Vesting & Option Grant

Dyadic International's President & COO, Joseph P. Hazelton, increased his beneficial ownership through the vesting of 36,418 restricted stock units and the grant of 67,250 stock options.

Summary

• Joseph P. Hazelton, President & COO of Dyadic International Inc. (DYAI), reported an increase in his beneficial ownership.
• He acquired 36,418 shares of common stock on January 2, 2026, through the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted as part of the Issuer's key employee annual bonus for the year ended 2025, in lieu of a cash bonus, and vested in full upon grant.
• Following this transaction, Mr. Hazelton directly beneficially owns 191,758 shares of common stock.
• Additionally, Mr. Hazelton was granted 67,250 stock options on January 2, 2026, with an exercise price of $0.94 per share.
• These stock options are an annual grant and will vest in four equal installments, beginning on the first anniversary of the grant date (January 2, 2027), subject to continued service.
• The stock options have an expiration date of January 2, 2036.
• Following this grant, Mr. Hazelton directly beneficially owns 67,250 stock options.

Sentiment

Score: 6

Explanation: Slightly positive. The increase in insider ownership through equity awards aligns management's interests with shareholders and is a routine, expected compensation event, indicating stability in executive incentives.

Positives

• The President & COO, Joseph P. Hazelton, increased his direct beneficial ownership in the company, which can signal management confidence.
• The vesting of RSUs and grant of stock options align management's interests with those of shareholders.

Future Outlook

The stock options granted to Joseph P. Hazelton will vest in four equal installments, commencing on January 2, 2027, contingent upon his continued service to the Issuer. This provides a future incentive for his ongoing commitment to the company.

Management Comments

• The RSUs were granted pursuant to the Issuer's key employee annual bonus, in lieu of a cash bonus earned for the year ended 2025, and vested in full upon grant.
• The stock options represent an annual grant, with vesting tied to continued service to the Issuer.

Industry Context

This Form 4 filing reflects routine executive compensation practices within the biotechnology or industrial enzymes industry, where equity-based incentives like RSUs and stock options are commonly used to attract, retain, and motivate key management personnel. Such grants align executive performance with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as part of executive compensation is a standard practice across various industries, including biotechnology and specialty chemicals, similar to companies like Novozymes or Codexis.
• Granting RSUs in lieu of cash bonuses is a common strategy to conserve cash and further align executive interests with long-term company performance, a practice observed in many growth-oriented companies.
• The vesting schedule for stock options, typically over several years, is also standard, designed to encourage long-term commitment and performance, comparable to incentive structures at peers.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity ownership and long-term incentives.
• Employees: The RSU grant in lieu of a cash bonus for a key employee indicates a strategy to retain talent through equity, potentially impacting overall employee compensation philosophy.

Next Steps

• The stock options granted to Joseph P. Hazelton will begin vesting in four equal installments starting on January 2, 2027, subject to his continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, specifically the vesting of RSUs and the grant of stock options. While an increase in insider ownership is generally a positive signal of management alignment, this specific transaction is an expected part of an executive's compensation package and does not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to 'hold' based on broader company fundamentals and market conditions, as this filing alone does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Dyadic International, DYAI, Joseph P. Hazelton, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Beneficial Ownership